🇺🇸 FDA
Pipeline program

ATI-045

ATI-045-AD-201

Phase 2 small_molecule active

Quick answer

ATI-045 for Atopic Dermatitis is a Phase 2 program (small_molecule) at Aclaris Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Aclaris Therapeutics
Indication
Atopic Dermatitis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials